African Americans (AAs) and European Americans (EuAms) display differences in cardiovascular risk factors and mortality from cardiovascular disease (CVD). AAs show a higher prevalence than EuAms in most cardiovascular risk factors.
Telomere Length Dynamics
Comprising TTAGGG tandem repeats and their telomerebinding protein complex (shelterin), mammalian telomeres safeguard the ends of the chromosomes. 22 As somatic cells divide, their telomeres undergo progressive shorteninga process that ultimately leads to cessation of replication, that is, replicative senescence. 23 In humans, embryonic stem cells express the enzyme telomerase-a reverse transcriptase that adds telomere repeats to the ends of the chromosomes, thereby preventing telomere shortening during early intrauterine life. 24 However, because telomerase is repressed in somatic tissues during extrauterine life, age-dependent telomere shortening in these tissues largely reflects the replicative histories of stem cells/progenitor cells on top of the somatic cell hierarchy. 25 In this way, telomere length (TL) in skeletal muscle-a minimally proliferative tissue-is longer than TL in leukocytes, which represent the highly proliferative hematopoietic system. 26 Moreover, to accommodate the demands of the growing soma, stem cell/progenitor cell replication is much faster during growth and development. Therefore, the rate of telomere shortening is much faster in childhood than during adulthood. 26, 27 Most epidemiologic studies have used leukocyte TL (LTL) as a proxy for TL in other somatic tissues, given that TL is proportional across somatic tissues within the individual, that is, a person with short (or long) TL in 1 somatic tissue has short (or long) TL in other somatic tissues, 26 regardless of the replicative history of these tissues. This is because, at birth and throughout the life course, the variation in TL, which is highly heritable, 28 across individuals is much wider than TL variation across somatic tissues within the individual.
TL Evolution Across Mammals
Why is TL in humans as long as it is? Moreover, is this length arbitrary or is it determined by evolutionary principles? TL is short, and telomerase activity in somatic tissues is repressed in long-lived, large mammals compared with short-lived, small mammals. 29 One potential explanation for these findings is that short telomeres and repressed telomerase diminish cancer risk by curtailing replicative potential. 25, 30, 31 The trade-off might be diminished tissue repair through cell replication and, therefore, increased propensity to degenerative diseases. Thus, across long-lived, large mammals, telomeres might converge to an optimal length that strikes a balance between cancer and degenerative diseases during the life course of animals from a given species.
TL is short in humans compared with most mammals. 29 Still, TL variance across the general population is considerable, amounting to 3 to 4 kilobases. 27, 32 Detrimental mutations in telomere-maintenance genes can result in specific diseases that are the outcome of extremely short TL 29 , but these diseases are relatively rare. The question then is whether in the general population, individuals with constitutively short telomeres have a higher risk for degenerative diseases. This might be the case for atherosclerosis, which is perhaps the main degenerative disease that afflicts contemporary humans.
TL and Atherosclerosis
Two meta-analyses concluded that short LTL is associated with CVD, based on data from individuals of principally European ancestry. 33, 34 In general, short LTL is associated with arterial aging, as expressed in arterial stiffness, 35 coronary artery calcifications, 36, 37 and severity of atherosclerotic plaques in the coronary arteries 38, 39 and the carotid arteries. [40] [41] [42] [43] What might be the explanation for these associations? For years, the dominant thinking in telomere epidemiology has been that LTL is a passive biomarker of the cumulative burden of inflammation and oxidative stress during adult life. Thus, individuals with a higher burden of inflammation and oxidative stress, including obese individuals, smokers, patients with diabetes mellitus, and those with atherosclerotic CVD, were presumed to have a faster age-dependent LTL shortening during adult life. 44 However, the variation in LTL across adults of the same age is largely the outcome of the interindividual variation in LTL during the first 2 decades of life 27, 32 rather than interindividual variation in the rate of LTL attrition during adulthood. 45 Thus, short LTL might precede by several decades the manifestations of atherosclerotic CVD and related metabolic risks. 46, 47 For instance, short LTL is observed long before the onset of carotid lesions and predicts their progression over time. 40 Short LTL also precedes the clinical manifestation of insulin resistance. 47, 48 Moreover, not only short LTL but also singlenucleotide polymorphisms associated with short LTL 39,49 are associated with increased propensity for atherosclerotic CVD.
These findings principally exclude reverse causality, that is, atherosclerotic CVD engenders short LTL, supporting the thesis that short LTL antecedes the clinical manifestations of atherosclerotic CVD.
Longer LTL in Individuals of Recent African Ancestry Than in Individuals of Recent European Ancestry
In light of the short LTL-CVD association, it is noteworthy that compared with EuAms, AAs display not only a longer LTL [19] [20] [21] 50 but also a higher prevalence than EuAMs of single-nucleotide polymorphisms associated with a longer TL. 51 Although the underlying reasons are not well understood, findings that LTL of sub-Saharan Africans is even longer than that of AAs suggest that the northbound migration from equatorial Africa might have resulted in TL shortening in Europeans. 20 One potential cause of telomere shortening in Europeans might be melanoma. Previous investigators had excluded melanoma as an evolutionary force. 52 However, given that not only longer LTL but also alleles associated with longer LTL are over-represented in patients with melanoma, 53,54 without evolutionary-driven telomere shortening, whites of European ancestry would have been more susceptible to melanoma than they are at present.
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TL and Mortality Crossover Between AAs and EuAms
Overall, AAs have a shorter life expectancy than EuAms. However, after the age of 80, AAs display a longer life expectancy than EuAms-a phenomenon referred to as the mortality crossover. 55, 56 Corti et al 55 reported that after 80 years of age, AAs had a 25% lower risk of all-cause mortality than EuAms-a difference that was attributed to a 55% lower atherosclerotic-coronary heart disease mortality in AAs. Other studies suggested that socioeconomic status and other 56, 57 However, in most of these studies, the mortality crossover remained significant after adjustments for environmental factors. 55 Thus, the mortality crossover might be related to different trajectories of coronary heart disease, which could be partially explained by the longer LTL in AAs versus EuAms.
Conclusions and Perspectives
Since the inception of the discipline of telomere epidemiology, LTL has been regarded as a passive biomarker of aging and atherosclerotic CVD. However, an emerging body of research points to an active role of TL in atherosclerosis, which is reason enough to seek further insights into the potential role of TL in the different propensities of AAs and EuAms to atherosclerotic CVD. The longer LTL in AAs than EuAms might partially explain the less susceptibility of AAs than EuAms to atherosclerosis and their longer life expectancy after 80 years of age. Perhaps, the first step toward gaining further insight into these intriguing ethnic differences is to perform large-scale genome-wide association studies of LTL in multiple ethnic groups. Identifying new LTL-associated single-nucleotide polymorphisms might help construct a comprehensive genetic map leading to mechanistic insights into the role of TL, as expressed in LTL, in a host of human diseases.
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